JP7682103B2 - シロリムスまたはその塩を含有する水性懸濁組成物 - Google Patents

シロリムスまたはその塩を含有する水性懸濁組成物 Download PDF

Info

Publication number
JP7682103B2
JP7682103B2 JP2021567672A JP2021567672A JP7682103B2 JP 7682103 B2 JP7682103 B2 JP 7682103B2 JP 2021567672 A JP2021567672 A JP 2021567672A JP 2021567672 A JP2021567672 A JP 2021567672A JP 7682103 B2 JP7682103 B2 JP 7682103B2
Authority
JP
Japan
Prior art keywords
aqueous suspension
suspension composition
sirolimus
salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021567672A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021132565A5 (https=
JPWO2021132565A1 (https=
Inventor
豊実 藤澤
礼華 芥川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of JPWO2021132565A1 publication Critical patent/JPWO2021132565A1/ja
Publication of JPWO2021132565A5 publication Critical patent/JPWO2021132565A5/ja
Priority to JP2025080159A priority Critical patent/JP2025111828A/ja
Application granted granted Critical
Publication of JP7682103B2 publication Critical patent/JP7682103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021567672A 2019-12-26 2020-12-25 シロリムスまたはその塩を含有する水性懸濁組成物 Active JP7682103B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080159A JP2025111828A (ja) 2019-12-26 2025-05-13 シロリムスまたはその塩を含有する水性懸濁組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019237226 2019-12-26
JP2019237226 2019-12-26
PCT/JP2020/048738 WO2021132565A1 (ja) 2019-12-26 2020-12-25 シロリムスまたはその塩を含有する水性懸濁組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080159A Division JP2025111828A (ja) 2019-12-26 2025-05-13 シロリムスまたはその塩を含有する水性懸濁組成物

Publications (3)

Publication Number Publication Date
JPWO2021132565A1 JPWO2021132565A1 (https=) 2021-07-01
JPWO2021132565A5 JPWO2021132565A5 (https=) 2023-09-11
JP7682103B2 true JP7682103B2 (ja) 2025-05-23

Family

ID=76575568

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567672A Active JP7682103B2 (ja) 2019-12-26 2020-12-25 シロリムスまたはその塩を含有する水性懸濁組成物
JP2025080159A Pending JP2025111828A (ja) 2019-12-26 2025-05-13 シロリムスまたはその塩を含有する水性懸濁組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080159A Pending JP2025111828A (ja) 2019-12-26 2025-05-13 シロリムスまたはその塩を含有する水性懸濁組成物

Country Status (9)

Country Link
US (1) US20230055121A1 (https=)
EP (1) EP4082544A4 (https=)
JP (2) JP7682103B2 (https=)
KR (1) KR20220122612A (https=)
CN (2) CN118340726A (https=)
AU (1) AU2020411442B2 (https=)
CA (1) CA3162626A1 (https=)
TW (1) TWI871406B (https=)
WO (1) WO2021132565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942607A (zh) * 2023-01-13 2023-10-27 杭州微致生物科技有限公司 一种西罗莫司混悬液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536797A (ja) 2007-08-16 2010-12-02 マクサイト， インコーポレイテッド 眼の疾患または状態を治療するための製剤
CN106420607A (zh) 2016-11-02 2017-02-22 北京诺康达医药科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN107334734A (zh) 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CN105073112B (zh) 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
CN105833344B (zh) * 2016-04-26 2019-04-26 青岛慧生惠众生物科技有限公司 一种可注射水凝胶在制备眼内填充物中的应用
EP3565520B1 (en) * 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536797A (ja) 2007-08-16 2010-12-02 マクサイト， インコーポレイテッド 眼の疾患または状態を治療するための製剤
CN106420607A (zh) 2016-11-02 2017-02-22 北京诺康达医药科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN107334734A (zh) 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂

Also Published As

Publication number Publication date
WO2021132565A1 (ja) 2021-07-01
TWI871406B (zh) 2025-02-01
AU2020411442B2 (en) 2026-02-12
KR20220122612A (ko) 2022-09-02
CA3162626A1 (en) 2021-07-01
AU2020411442A1 (en) 2022-06-23
JPWO2021132565A1 (https=) 2021-07-01
US20230055121A1 (en) 2023-02-23
CN118340726A (zh) 2024-07-16
EP4082544A4 (en) 2024-01-10
JP2025111828A (ja) 2025-07-30
TW202135806A (zh) 2021-10-01
CN114845714A (zh) 2022-08-02
CN114845714B (zh) 2024-05-14
EP4082544A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
US11826429B2 (en) Pharmaceutical composition comprising brinzolamide
JP2020040968A (ja) シクロスポリンａ２型の懸濁剤
ES2878107T3 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
KR102175622B1 (ko) 마이봄 기능부전의 치료제
JP2024161426A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
US20240390515A1 (en) Multidose ophthalmic compositions
WO2018056269A1 (ja) Ｊａｋ阻害剤を含有する点眼剤
JP2025111828A (ja) シロリムスまたはその塩を含有する水性懸濁組成物
KR20160060656A (ko) 폴리에틸렌글리콜 함유 조성물
US6274609B1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
WO2018056268A1 (ja) 炎症性眼疾患の治療及び／又は予防剤
RU2842860C1 (ru) Водная суспензионная композиция, содержащая сиролимус или его соль
CA2866810C (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
KR20230107624A (ko) 레보플록사신 및 케토롤락을 함유하는 안과용 조성물, 이의 제조 방법 및 용도
JP2007016024A (ja) ロフルミラスト点眼液
KR20170129832A (ko) 폴리펩티드를 함유하는 의약 조성물
EA051764B1 (ru) Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250513

R150 Certificate of patent or registration of utility model

Ref document number: 7682103

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150